Showing 5621-5630 of 8791 results for "".
- Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosahttps://practicaldermatology.com/news/abeona-therapeutics-provides-update-on-eb-101-gene-therapy-for-severe-form-of-epidermolysis-bullosa/2458202/Abeona Therapeutics, Inc. has announced updated clinical data from the ongoing Phase 1/2 clinical trial for the EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB), a severe fo
- Foamix Announces Additional Phase 3 Trial for FMX101 in Moderate to Severe Acnehttps://practicaldermatology.com/news/foamix-announces-additional-phase-3-trial-for-fmx101-in-moderate-to-severe-acne/2458203/Foamix Pharmaceuticals is launching an additional Phase 3 trial for FMX101 in moderate to severe acne, a topical minocycline treatment. If the results are positive, this new Phase 3 trial is expected to form the basis for a New Drug Application (NDA) which the company plans to submit in t
- Forging Ahead For Clear-Cut Best Practices for MOHS Surgeryhttps://practicaldermatology.com/news/forging-ahead-for-clear-cut-best-practices-for-mohs-surgery/2458204/New research on the average number of surgical slices made during Mohs micrographic surgery (MMS) will serve as a first step towards identifying best practices for MMS, as well as identifying and informing physicians who may need re-training because their practice patterns deviate far from their
- Coolibar Gets Gross To Prevent Skin Cancerhttps://practicaldermatology.com/news/coolibar-gets-gross-to-prevent-skin-cancer/2458206/Sun protective clothing and accessory maker Coolibar’s new skin cancer prevention and awareness campaign may make you sick, and that’s kind of the point. Called "Let's Get Gross," the new campaign will feature stories f
- Non-Invasive Pigmented Lesion Assay Almost Doubles Biopsy Specificityhttps://practicaldermatology.com/news/use-of-non-invasive-pigmented-lesion-assay-almost-doubles-biopsy-specificity/2458209/Dermatologists who incorporate Dermtech’s noninvasive pigmented lesion assay will biopsy fewer benign pigmented skin lesions and miss fewer melanomas, according to a new study in JAMA Dermatology
- Paratek: Phase 3 Data Show Omadacycline Effective Against Common Skin Pathogens, Including MRSAhttps://practicaldermatology.com/news/paratek-phase-3-data-show-omadacycline-effective-against-common-skin-pathogens-including-mrsa/2458211/Analysis of microbiology data from a Phase 3 study of omadacycline in acute skin infections shows that once-daily treatment with IV-to-oral omadacycline is effective in treating the most frequently isolated bacterial pathogens associated with skin infections, including methicillin-resistant S
- RxPhoto Releases Updated HIPPA-Compliant Mobile Clinical Photography Apphttps://practicaldermatology.com/news/rxphoto-releases-updated-mobile-hippa-compliant-clinical-photo-app/2458213/RxPhoto has released version 3 of its mobile medical photography solution for medical practices and providers. Medical practices can now remain HIPAA compliant while using their mobile devices to securely capture, manage and share medical photos and videos.
- Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ as Lowest Priced Injectable Biologic For Psoriasishttps://practicaldermatology.com/news/valeants-patient-access-and-pricing-committee-announces-pricing-for-siliq-as-lowest-priced-injectable-biologic-for-psoriasis/2458215/Following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), Valeant Pharmaceuticals International, Inc. has decided to list SILIQ (brodalumab) injection at $3,500 per month, which is the lowest injectable biologic psoriasis treatment cur
- BioPharmX Completes Phase 2b Trial of BPX-01; Topline Results Coming Soonhttps://practicaldermatology.com/news/biopharmx-completes-phase-2b-trial-of-bpx-01-topline-results-coming-soon/2458217/BioPharmX Corporation completed their last subject visit in a Phase 2b trial of their investigational acne drug, BPX-01, and the last site close-out visit was April 7, 2017. The company now plans to announce topline data from the trial in the fi
- ThermiGen, an Almirall company, Names Vladimir Paul-Blanc President & General Managerhttps://practicaldermatology.com/news/thermigen-an-almirall-company-names-vladimir-paul-blanc-president-general-manager/2458219/Vladimir Paul-Blanc has been named President & General Manager of ThermiGen, LLC, starting May 1. He will report directly to the Executive Vice-president of Commercial Strategy of Almirall, Alfonso Ugarte, and he will be responsible for all general management responsibilities for the Thermi b